Biomedical Engineering Reference
In-Depth Information
176. Breedveld P, Beijnen JH, Schellens JHM. 2006. Use of P-glycoprotein and BCRP in-
hibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends
Pharmacol Sci 27: 17-24.
177. Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O'Reilly T, Buchdunger E,
Black PM, Stiles CD. 2000. Intracranial inhibition of platelet-derived growth factor-
mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-pheny-
laminopyrimidine class. Cancer Res 60: 5143-5150.
178. Petzer AL, Gunsilius E, Hayes M, Stockhammer G, Duba HC, Schneller F, Grunewald
K, Poewe W, Gastl G. 2002. Low concentrations of STI571 in the cerebrospinal fluid: a
case report. Br J Haematol 117: 623-625.
179. Takayama N, Sato N, O'Brien SG, Ikeda Y, Okamoto S. 2002. Imatinib mesylate has lim-
ited activity against the central nervous system involvement of Philadelphia chromosome-
positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid.
Br J Haematol 119: 106-108.
180. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schel-
lens JH. 2005. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain
penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer re-
sistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib
in patients. Cancer Res 65: 2577-2582.
181. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. 2000. Increased drug delivery to the
brain by P-glycoprotein inhibition. Clin Pharmacol Ther 68: 231-237.
182. Honjo Y, Morisaki K, Huff LM, Robey RW, Hung J, Dean M, Bates SE. 2002.
Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2
(MXR/BCRP/ABCP1). Cancer Biol Ther 1: 696-702.
183. Imai Y, Nakane M, Kage KM, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, Sugimoto
Y. 2002. C421A polymorphism in the human breast cancer resistance protein gene is
associated with low expression of Q141K protein and low-level drug resistance. Mol
Cancer Ther 1: 611-616.
184. Iida A, Saito S, Sekine A, Mishima C, Kitamura Y, Kondo K, Harigae S, Osawa S,
Nakamura Y. 2002. Catalog of 605 single-nucleotide polymorphisms (SNPs) among
13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8,
ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and
ABCG8. J Hum Genet 47: 285-310.
185. Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD, Schuetz EG. 2003.
Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship
to BCRP expression in human intestine. Pharmacogenetics 13: 19-28.
186. Bosch TM, Kjellberg LM, Bouwers A, Koeleman BP, Schellens JH, Beijnen JH, Smits
PH, Meijerman I. 2005. Detection of SNPs in the ABCG2 gene in a Dutch population.
Am J Pharmacogenom 5: 123-131.
187. de Jong FA, Marsh S, Mathijssen RH, King C, Verweij J, Sparreboom A, McLeod HL.
2004. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment
of influence on irinotecan disposition. Clin Cancer Res 10: 5889-5894.
188. Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, Suzuki H, Nanba
E, Oshimura M, Terakawa N, et al. 2005. Functional assessment of abcg2 (bcrp) gene
polymorphisms to protein expression in human placenta. Drug Metab Dispos 33: 94-101.
Search WWH ::
Custom Search